The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite ...

The stock of Caris Life Sciences shined in its Nasdaq debut on Wednesday, pricing its heavily-subscribed initial public ...

Caris Life Sciences' shares jumped nearly 29% in their New York debut on Wednesday, fetching the cancer diagnostic firm a ...

Caris Life Sciences raised $494.1 million in its Nasdaq initial public offering, the cancer diagnostic firm said on Tuesday, ...

Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, ...

Caris Life Sciences Inc., a health care company that uses technology to help diagnose and treat cancer, raised $494 million ...

Caris Life Sciences bumped up the pricing of its IPO to raise more than $494.1 million in its Nasdaq debut—well over the ...

Caris Life Sciences shares rose on their first day of trading in their debut on Nasdaq. The biotechnology company started trading at $27 each on Wednesday afternoon, a day after the company's IPO was ...

The biotech firm filed its IPO paperwork May 23 in a bid to boost its finances, noting there was "substantial doubt" about ...

Caris Life Sciences, an AI-driven precision oncology company, is targeting a $5.35 billion valuation in its U.S. initial ...

With the successful IPO of Caris Life Sciences makes its founder David Dean Halbert worth an estimated $3.3 billion.

Along with its Caris Assure liquid biopsy test for treatment selection and its MI Profile tumor tissue sequencing platform, ...